Claims
- 1. A compound represented by the formula: or a pharmaceutically acceptable salt, prodrug or ester thereof, whereinR2 is an alkyl, aryl, cycloalkyl, cycloalkylalkyl or aralkyl radical, which radical is optionally substituted with a radical selected from the group consisting of alkyl, halo, nitro, cyano, CF31, —OR9, and —SR9, wherein R9 is a radical selected from the group consisting of hydrogen and alkyl; R3 is a hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, alkylsulfonylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, aminoalkyl or mono- or disubstituted aminoalkyl radicals, wherein said substituents are selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl and heterocycloalkylalkyl radicals; or where said aminoalkyl radical is disubstituted, said substituents along with the nitrogen atom to which they are attached, form a heterocycloalkyl or a heteroaryl radical; R4 is an alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, aralkenyl, heteroaralkyl, aminoalkyl or mono- or disubstituted aminoalkyl radical, wherein said substituents are selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl and heterocycloalkylalkyl radicals; or where said aminoalkyl radical is disubstituted, said substituents along with the nitrogen atom to which they are attached, form a heterocycloalkyl or a heteroaryl radical; R6 is a hydrogen or alkyl radical; x is 1 or 2; t is 0 or 1; and Y is O or S; and A is an alkoxy, alkenoxy, aralkoxy, alkyl, cycloalkyl, cycloalkylalkoxy, cycloalkylalkyl, aralkyl, aryl, aryloxy, heterocycloalkyl, heterocycloalkoxy, heterocycloalkylalkyl, heterocycloalkylalkoxy, heteroaralkyl, heteroaralkoxy, heteroaryloxy, heteroaryl, alkenyl, aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl, amino, or mono- or disubstituted amino radical, wherein the substituents are selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl and heterocycloalkyalkyl radicals; or where said amino radical is disubstituted, said substituents along with the nitrogen atom to which they are attached form a heterocycloalkyl or heteroaryl radical; or is represented by the formula wherein R is a hydrogen, alkoxycarbonyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, carboxyalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl, heterocyclylcarbonyl, heterocyclyloxycarbonyl, heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl, heteroaryloxy-carbonyl, heteroaroyl, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl, aminocarbonyl, aminoalkanoyl, or mono- or disubstituted aminocarbonyl or mono- or disubstituted aminoalkanoyl radical, wherein the substituents are selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl and heterocycloalkyalkyl radicals; or wherein said aminocarbonyl or aminoalkanoyl radicals are disubstituted, said substituents along with the nitrogen atom to which they are attached form a heterocycloalkyl or heteroaryl radical; R′ is a radical as defined for R3 or R″SO2—, wherein R″ is a radical as defined for R3; or R and R″ together with the nitrogen to which they are attached form a heterocycloalkyl or heteroaryl radical; R1 is a hydrogen, —CO2CH3, —CH2CO2CH3, —CO2H, —CH2CO2H, —CH2CH2CONH2, —CH2CONH2, —CONH2, —CH2C(O)NHCH3, —CH2C(O)N(CH3)2, —CONHCH3, —CONH(CH3)2, —CH2SO2NH2, —CH2CH2SO2NH2, —CH2S[O]CH3, —CH2S[O]2CH3, —C(CH3) 2(SCH3), —C(CH3)2(S[O]CH3), —C(CH3)2(S[O]2CH3), alkyl, hydroxyalkyl, cyanoalkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, alkylthioalkyl, aralkyl, heteroaralkyl, aminoalkyl or mono- or disubstituted aminoalkyl radical, wherein said substituents are selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl and heterocycloalkylalkyl radicals; or where said aminoalkyl radical is disubstituted, said substituents along with the nitrogen atom to which they are attached, form a heterocycloalkyl or a heteroaryl radical; and each of R1′ and R1″ are independently a radical as defined for R1; or one of R1′ and R1″ together with R1 and the carbon atoms to which R1, R1′ and R1″ are attached, form a cycloalkyl radical.
RELATED APPLICATION
This application is a continuation of Ser. No. 09/288,080 filed Apr. 8, 1999, U.S. Pat. No. 6,248,775, which is a continuation of Ser. No. 08/294,468 filed Aug. 23, 1994 now U.S. Pat. No. 5,968,942 which is a continuation in part application of co-owned and U.S. patent application Ser. No. 08/204,827 filed Mar. 2, 1994, U.S. Pat. No. 6,060,476 which is a continuation in part application of co-owned PCT/US93/07814 and Ser. No. 08/110,911, now U.S. Pat. No. 5,843,946, both filed Aug. 24, 1993, which is a continuation in part application of co-owned U.S. patent application Ser. No. 07/934,984 filed Aug. 25, 1992, now abandoned, each of which is incorporated herein by reference in its entirety.
US Referenced Citations (26)
Foreign Referenced Citations (23)
Number |
Date |
Country |
A-7982387 |
Apr 1988 |
AU |
104041 |
Mar 1984 |
EP |
114993 |
Jun 1984 |
EP |
172347 |
Feb 1986 |
EP |
223437 |
May 1987 |
EP |
0 264 795 |
Apr 1988 |
EP |
337714 |
Oct 1989 |
EP |
0 342 541 |
Nov 1989 |
EP |
0 346 847 |
Dec 1989 |
EP |
356223 |
Feb 1990 |
EP |
389898 |
Oct 1990 |
EP |
393445 |
Oct 1990 |
EP |
393457 |
Oct 1990 |
EP |
402646 |
Dec 1990 |
EP |
468641 |
Jan 1992 |
EP |
2 184 730 |
Jul 1987 |
GB |
2 200 115 |
Jul 1988 |
GB |
2 209 752 |
Aug 1989 |
GB |
WO8403044 |
Aug 1984 |
WO |
9208699 |
May 1992 |
WO |
9404492 |
Mar 1994 |
WO |
WO9405639 |
Mar 1994 |
WO |
WO 9933792 |
Apr 1999 |
WO |
Non-Patent Literature Citations (8)
Entry |
Roberts et al, “Rational Design of Peptide-based Proteinase Inhibitors,” Science, 248, 358 (1990). |
Erickson et al, “Design Activity and 2.8A Crystal Structure of a C2 Symmetric Inhibitor Complexed to HIV-1 Protease,” Science, 249 527 (1990). |
Pearl et al, “Sequence specificity of retroviral proteases,” Nature, 328 (1987). |
Martin, Drugs of the Future, 16(3), 210-212 (1991). |
Meek et al, Letter to Nature, 343, 90-92 (1990). |
McQuade et al, “A Synthetic HIV-1 Protease Inhibitor with Antiviral Activity Arrests HIV-like Particle Maturation,” Science, 454-456 (1990). |
Rich et al, “Peptide Inhibitors of Proteases,” Design of Protease Inhibitors 511-520 (1984). |
Rosenberg et al J. Med. Chem., 30, 1224-1228 (1987). |
Continuations (2)
|
Number |
Date |
Country |
Parent |
09/288080 |
Apr 1999 |
US |
Child |
09/798255 |
|
US |
Parent |
08/294468 |
Aug 1994 |
US |
Child |
09/288080 |
|
US |
Continuation in Parts (4)
|
Number |
Date |
Country |
Parent |
08/204827 |
Mar 1994 |
US |
Child |
08/294468 |
|
US |
Parent |
PCT/US93/07814 |
Aug 1993 |
US |
Child |
08/204827 |
|
US |
Parent |
08/110911 |
Aug 1993 |
US |
Child |
PCT/US93/07814 |
|
US |
Parent |
07/934984 |
Aug 1992 |
US |
Child |
08/110911 |
|
US |